US5668255A
(en)
*
|
1984-06-07 |
1997-09-16 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
US6022950A
(en)
*
|
1984-06-07 |
2000-02-08 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
US5169939A
(en)
*
|
1985-05-21 |
1992-12-08 |
Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College |
Chimeric antibodies
|
US6051405A
(en)
*
|
1986-09-24 |
2000-04-18 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Constructs encoding recombinant antibody-toxin fusion proteins
|
US4892827A
(en)
*
|
1986-09-24 |
1990-01-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
|
AU3751689A
(en)
*
|
1988-05-09 |
1989-11-29 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Vector for secretion of proteins directly into periplasm or culture medium
|
US5206353A
(en)
*
|
1988-07-23 |
1993-04-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
CD-4/cytotoxic gene fusions
|
US5169933A
(en)
*
|
1988-08-15 |
1992-12-08 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
US5135736A
(en)
*
|
1988-08-15 |
1992-08-04 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
US5149782A
(en)
*
|
1988-08-19 |
1992-09-22 |
Tanox Biosystems, Inc. |
Molecular conjugates containing cell membrane-blending agents
|
ZA898139B
(en)
*
|
1988-11-17 |
1990-08-29 |
Hoffmann La Roche |
Recombinant interleukin-2 hybrid proteins
|
DK0383599T3
(da)
*
|
1989-02-17 |
1996-08-05 |
Merck & Co Inc |
Protein-anticancermiddel
|
US6406697B1
(en)
*
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5621078A
(en)
*
|
1989-03-22 |
1997-04-15 |
Merck & Co., Inc. |
Modified pseudomonas exotoxin PE40
|
IL93723A
(en)
*
|
1989-03-22 |
1997-02-18 |
Merck & Co Inc |
Cystein modified truncated pseudomonas exotoxin A
|
AU641392B2
(en)
*
|
1989-04-21 |
1993-09-23 |
Protein Design Laboratories, Inc. |
Recombinant antibody-toxin fusion protein
|
US6207798B1
(en)
|
1989-08-03 |
2001-03-27 |
Merck & Co., Inc. |
Modified PE40 toxin fusion proteins
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
CA2071946A1
(en)
*
|
1989-12-21 |
1991-06-22 |
Ira H. Pastan |
Toxin for construction of immunotoxins
|
CA2072891C
(en)
*
|
1990-01-02 |
1999-12-21 |
Ira Pastan |
Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity
|
US5458878A
(en)
*
|
1990-01-02 |
1995-10-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
|
US5110912A
(en)
*
|
1990-03-02 |
1992-05-05 |
Seragen, Inc. |
Purification of il-2-containing hybrid compounds
|
DK0531434T3
(da)
*
|
1990-05-11 |
2000-01-31 |
Us Health |
Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
US5241053A
(en)
*
|
1990-09-05 |
1993-08-31 |
Takeda Chemical Industries, Ltd. |
Fused proteins comprising glycoprotein gD of HSV-1 and LTB
|
US6099842A
(en)
*
|
1990-12-03 |
2000-08-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
|
US5571894A
(en)
*
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
CA2079879C
(fr)
*
|
1991-02-08 |
2007-11-06 |
Thierry Hercend |
Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs des lymphocytes humains ainsi que leurs applications
|
FR2672616B1
(fr)
*
|
1991-02-08 |
1994-09-23 |
Roussel Uclaf |
Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs de lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques.
|
CA2079881C
(fr)
*
|
1991-02-12 |
2007-11-06 |
Thierry Hercend |
Sequences nucleotidiques codant pour des regions variables de chaines .beta. des recepteurs des lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques
|
US5328984A
(en)
*
|
1991-03-04 |
1994-07-12 |
The United States As Represented By The Department Of Health & Human Services |
Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
|
US5223604A
(en)
*
|
1991-06-25 |
1993-06-29 |
S.P.I. Synthetic Peptides Incorporated |
Pseudomonas exoenzyme s peptide composition and method
|
US5939531A
(en)
*
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
CA2081952A1
(en)
*
|
1991-11-08 |
1993-05-09 |
John J. Donnelly |
Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use
|
ATE314475T1
(de)
*
|
1992-06-18 |
2006-01-15 |
Us Gov Health & Human Serv |
Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
|
GB9326174D0
(en)
*
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
AU706056B2
(en)
*
|
1995-10-13 |
1999-06-10 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Immunotoxin containing a disulfide-stabilized antibody fragment
|
HUP9901109A3
(en)
|
1996-03-01 |
1999-11-29 |
Novartis Ag |
Peptide immunogens for vaccination against and treatment of allergy
|
EP0941334B1
(en)
|
1996-11-06 |
2004-06-02 |
THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services |
Protease-activatable pseudomonas exotoxin a-like proproteins
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
US20020004113A1
(en)
*
|
1997-06-26 |
2002-01-10 |
Weder Donald E. |
Decorative cover for flower pot or floral grouping formed of polymeric materials having a texture or appearance simulating the texture or appearance of paper
|
US20030198772A1
(en)
*
|
1997-06-26 |
2003-10-23 |
Weder Donald E. |
Polymeric materials having a texture or appearance simulating the texture or appearance of paper
|
US7314632B1
(en)
*
|
1997-07-11 |
2008-01-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pseudomonas exotoxin A-like chimeric immunogens
|
AU731703B2
(en)
*
|
1997-07-11 |
2001-04-05 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Pseudomonas exotoxin A-like chimeric immunogens
|
US20030054012A1
(en)
*
|
2000-05-12 |
2003-03-20 |
Fitzgerald David J. |
Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
|
US6077676A
(en)
*
|
1997-12-18 |
2000-06-20 |
Spectral Diagnostics, Inc. |
Single-chain polypeptides comprising troponin I and troponin C
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
AU2004201055B2
(en)
*
|
1998-04-24 |
2007-08-23 |
The Regents Of The University Of California |
Internalizing ErbB2 antibodies
|
US6794128B2
(en)
*
|
1998-04-24 |
2004-09-21 |
The Regents Of The University Of California |
Methods of selecting internalizing antibodies
|
US20020142000A1
(en)
*
|
1999-01-15 |
2002-10-03 |
Digan Mary Ellen |
Anti-CD3 immunotoxins and therapeutic uses therefor
|
US20030143233A1
(en)
*
|
1999-06-07 |
2003-07-31 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
US20030103948A1
(en)
*
|
1999-06-07 |
2003-06-05 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
US6838553B1
(en)
*
|
1999-10-05 |
2005-01-04 |
Academia Sinica |
Peptide repeat immunogens
|
US7078486B2
(en)
*
|
1999-12-10 |
2006-07-18 |
Spectral Diagnostics, Inc. |
Single-chain polypeptides comprising troponin I and troponin C
|
US20030104987A1
(en)
*
|
2001-04-25 |
2003-06-05 |
Weigel Paul H. |
Methods of using the hyaluronan receptor for endocytosis
|
CA2410024A1
(en)
*
|
2000-04-25 |
2001-11-01 |
The Board Of Regents Of The University Oklahoma |
Identification and uses of a hyaluronan receptor
|
US20050287638A1
(en)
*
|
2000-04-25 |
2005-12-29 |
Weigel Paul H |
Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
|
EP1379550B1
(en)
*
|
2000-12-21 |
2009-03-11 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
|
ES2342929T3
(es)
|
2001-09-26 |
2010-07-19 |
The Government of the United States of America as represented by the Secretary of Health and Human |
Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22.
|
CA2466443A1
(en)
*
|
2001-11-09 |
2003-05-15 |
Neopharm, Inc. |
Selective treatment of il-13 expressing tumors
|
WO2004087758A2
(en)
*
|
2003-03-26 |
2004-10-14 |
Neopharm, Inc. |
Il 13 receptor alpha 2 antibody and methods of use
|
CN100417414C
(zh)
|
2003-04-30 |
2008-09-10 |
苏黎世大学 |
免疫毒素在制备治疗头颈鳞状上皮细胞癌或膀胱癌药物中的应用
|
EP1689783B1
(en)
*
|
2003-11-25 |
2010-05-19 |
The Government Of The United States, As Represented by The Secretary Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
WO2006039238A2
(en)
*
|
2004-09-30 |
2006-04-13 |
The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Irta2 antibodies and methods of use
|
CA2583226A1
(en)
|
2004-10-04 |
2006-04-20 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against pseudomonas infection
|
CA2583202A1
(en)
*
|
2004-10-04 |
2006-04-27 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of macromolecules
|
CA2591992A1
(en)
|
2004-12-22 |
2006-06-29 |
The Salk Institute For Biological Studies |
Compositions and methods for producing recombinant proteins
|
AU2006247188A1
(en)
|
2005-05-18 |
2006-11-23 |
Children's Hospital & Research Center At Oakland |
Methods and compositions for immunizing against chlamydia infection
|
WO2007016150A2
(en)
|
2005-07-29 |
2007-02-08 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH |
Mutated pseudomonas exotoxins with reduced antigenicity
|
US20070148131A1
(en)
*
|
2005-12-05 |
2007-06-28 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of binding partners
|
CA2631952A1
(en)
*
|
2005-12-05 |
2007-06-14 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of antibodies
|
EP2010205A2
(en)
|
2006-03-16 |
2009-01-07 |
Trinity Biosystems, Inc. |
Methods for increasing the size of animals using needleless delivery constructs
|
EP1878744A1
(en)
*
|
2006-07-13 |
2008-01-16 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
|
US20090092660A1
(en)
*
|
2006-08-09 |
2009-04-09 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of particles
|
WO2009014650A2
(en)
|
2007-07-20 |
2009-01-29 |
The General Hospital Corporation |
Recombinant vibrio cholerae exotoxins
|
EP2197903B9
(en)
|
2007-09-04 |
2015-04-22 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
|
CN108129573B
(zh)
*
|
2007-09-21 |
2021-10-08 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
CN102655882B
(zh)
|
2009-09-11 |
2014-11-19 |
美国政府健康及人类服务部 |
具有降低的免疫原性的改进的假单胞菌外毒素a
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
NZ602958A
(en)
|
2010-03-30 |
2014-07-25 |
Pfenex Inc |
High level expression of recombinant toxin proteins
|
WO2011159835A1
(en)
|
2010-06-16 |
2011-12-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
CA2806314C
(en)
|
2010-07-30 |
2019-09-24 |
Medimmune, Llc |
Method for purifying active polypeptides or immunoconjugates
|
US11246915B2
(en)
|
2010-09-15 |
2022-02-15 |
Applied Molecular Transport Inc. |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
TWI689314B
(zh)
*
|
2010-11-30 |
2020-04-01 |
建南德克公司 |
低親和力血腦障壁受體抗體及其用途
|
US9206257B2
(en)
|
2011-04-19 |
2015-12-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
AU2012268013B2
(en)
|
2011-06-09 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
|
US8932586B2
(en)
|
2011-09-06 |
2015-01-13 |
Intrexon Corporation |
Modified forms of Pseudomonas exotoxin A
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
US9206240B2
(en)
|
2011-09-16 |
2015-12-08 |
The United States of America, as represented by the Secretary, Department of Helath and Human Services |
Pseudomonas exotoxin A with less immunogenic B cell epitopes
|
EP2764025B1
(en)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antibodies against hmw-maa
|
US9169304B2
(en)
|
2012-05-01 |
2015-10-27 |
Pfenex Inc. |
Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
|
CN104520331B
(zh)
|
2012-06-01 |
2018-09-07 |
美国政府(由卫生和人类服务部的部长所代表) |
磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
|
AU2013306076B2
(en)
|
2012-08-21 |
2018-01-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
US9416190B2
(en)
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
WO2014089354A1
(en)
|
2012-12-07 |
2014-06-12 |
The Regents Of The University Of California |
Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
WO2014093240A1
(en)
|
2012-12-10 |
2014-06-19 |
The General Hospital Corporation |
Bivalent il-2 fusion toxins
|
CN105007937B
(zh)
|
2012-12-20 |
2019-11-19 |
米迪缪尼有限公司 |
生产免疫偶联物的方法
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
US9388222B2
(en)
|
2013-10-06 |
2016-07-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified Pseudomonas exotoxin A
|
ES2764833T3
(es)
|
2013-10-11 |
2020-06-04 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
Anticuerpos contra TEM8 y su uso
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
AU2014352638B2
(en)
|
2013-11-25 |
2018-08-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
US10421958B2
(en)
|
2014-02-05 |
2019-09-24 |
Molecular Templates, Inc. |
Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
|
BR112016025866A2
(pt)
|
2014-05-07 |
2017-12-12 |
Applied Molecular Transp Llc |
composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão
|
ES2848857T3
(es)
|
2014-07-31 |
2021-08-12 |
Us Gov Health & Human Services |
Anticuerpos monoclonales humanos contra EphA4 y su uso
|
CA2961609C
(en)
|
2014-09-17 |
2023-03-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 antibodies (b7h3)
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
CA2981509A1
(en)
|
2015-03-30 |
2016-10-06 |
The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La |
Compositions comprising talens and methods of treating hiv
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
WO2017064190A1
(en)
|
2015-10-13 |
2017-04-20 |
Sanofi Pasteur |
Immunogenic compositions against s. aureus
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
CN108473575B
(zh)
|
2015-11-13 |
2022-04-19 |
美国卫生和人力服务部 |
抗-bcma多肽和蛋白质
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
US11066479B2
(en)
|
2016-08-02 |
2021-07-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
CA3045902A1
(en)
|
2016-12-21 |
2018-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
US11390683B2
(en)
|
2017-05-18 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides and proteins
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
US10849960B2
(en)
|
2017-09-08 |
2020-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
|
US11795235B2
(en)
|
2017-09-18 |
2023-10-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunotoxins with albumin binding domain
|
EP3691693A4
(en)
|
2017-10-06 |
2021-08-25 |
University Of Utah Research Foundation |
FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
|
ES2920428T3
(es)
|
2018-03-08 |
2022-08-03 |
Applied Molecular Transport Inc |
Constructos de administración derivados de toxinas para la administración oral
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟cd22特異的モノクローナル抗体およびその使用
|
US12012463B2
(en)
|
2018-08-08 |
2024-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
KR102353086B1
(ko)
*
|
2018-09-07 |
2022-01-20 |
아주대학교산학협력단 |
신규 면역독소 제조방법
|
IL282986B2
(en)
|
2018-11-07 |
2024-01-01 |
Applied Molecular Transport Inc |
Colics-derivative carriers for oral administration of heterologous cargo
|
SG11202104721RA
(en)
|
2018-11-07 |
2021-06-29 |
Applied Molecular Transport Inc |
Delivery constructs for transcytosis and related methods
|
US20220064324A1
(en)
|
2019-01-08 |
2022-03-03 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting mesothelin for treating solid tumors
|
CN113784987A
(zh)
|
2019-01-22 |
2021-12-10 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
|
US20220127368A1
(en)
|
2019-02-19 |
2022-04-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Bispecific immunotoxins targeting human cd25+ccr4+ tumors and regulatory t-cells
|
EA202290208A1
(ru)
|
2019-07-02 |
2022-03-25 |
Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз |
МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ
|
WO2021034727A1
(en)
|
2019-08-16 |
2021-02-25 |
Applied Molecular Transport Inc. |
Compositions, formulations, and interleukin production and purification
|
EP4031250A1
(en)
|
2019-10-22 |
2022-07-27 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
WO2021097289A1
(en)
|
2019-11-15 |
2021-05-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pegylated recombinant immunotoxins
|
WO2021173674A1
(en)
|
2020-02-26 |
2021-09-02 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
MX2023007178A
(es)
|
2020-12-22 |
2023-06-30 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
CN117500831A
(zh)
|
2021-06-09 |
2024-02-02 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
WO2023114980A1
(en)
|
2021-12-17 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
WO2024104584A1
(en)
|
2022-11-17 |
2024-05-23 |
University Of Cape Town |
Deimmunized pseudomonas exotoxin a
|